STOCK THE BANK

Houston Food Bank seeks volunteers for coronavirus quarantine kits

The Food Bank needs help packing quarantine food kits. Photo courtesy of Houston Food Bank

As the long lines at any local Costco suggest, the coronavirus/COVID 19 phenomenon has caused some to interpret news reports advising sensible precautions such as "wash your hands thoroughly" to mean "buy a car-full of toilet paper."

Talk of a potential quarantine has only added to the fervor, as citizens are advised to stock up on food for up to two weeks. But what of those who can't don masks and charge through sprawling stores looking for tuna packets?

The Houston Food Bank is asking that local residents assist those who do not have reserves of food in the event of service disruptions and closures. The non-profit has put out a call for volunteers to help pack essential quarantine food kits. The boxes are not yet being requested, but will be necessary in the event there is a need due to COVID-19 occurrences in their service area, according to the Food Bank.

"Hundreds of thousands of people are counting on the organization and its partners now, and this need will only heighten if the COVID-19 situation worsens," says Brian Greene, president/CEO of Houston Food Bank.

Volunteers can sign up for shifts online to help pack these boxes at the Food Bank, 535 Portwall St. Volunteer shifts run from 8 am to noon Monday–Saturday, from 6 pm to 9 pm Monday–Friday, and from 9 am to noon Sunday.

To quell any obvious concerns about safety, the Food Bank has increased the frequency of cleaning and disinfecting, especially around high-traffic areas, such as volunteer areas, elevators, meeting rooms, bathrooms, food areas.

Greene also notes that volunteers can bring much-needed items to donate and pack. The Food Bank's most-needed items include:

  • Rice
  • Pasta
  • Peanut butter
  • Canned protein
  • Soups
  • Jelly
  • Nutritious snacks
  • Canned Vegetable
  • Canned fruit
  • Hygiene items
  • Cleaning supplies: paper towels, disinfectant, bleach wipes
  • Bottled water

And, says Greene, "a little something sweet like cookies never hurt."

------

This article originally ran on CultureMap.

Trending News

Building Houston

 
 

Tvardi Therapeutics Inc. has fresh funds to support its drug's advancement in clinical trials. Photo via Getty Images

A Houston-based clinical-stage biopharmaceutical company has raised millions in its latest round.

Tvardi Therapeutics Inc. closed its $74 million series B funding round led by new investors New York-based Slate Path Capital, Florida-based Palkon Capital, Denver-based ArrowMark Partners, and New York-based 683 Capital, with continued support and participation by existing investors, including Houston-based Sporos Bioventures.

"We are thrilled to move out of stealth mode and partner with this lineup of long-term institutional investors," says Imran Alibhai, CEO at Tvardi. "With this financing we are positioned to advance the clinical development of our small molecule inhibitors of STAT3 into mid-stage trials as well as grow our team."

Through Slate Path Capital's investment, Jamie McNab, partner at the firm, will join Tvardi's board of directors.

"Tvardi is the leader in the field of STAT3 biology and has compelling proof of concept clinical data," McNab says in the release. "I look forward to partnering with the management team to advance Tvardi's mission to develop a new class of breakthrough medicines for cancer, chronic inflammation, and fibrosis."

Tvardi's latest fundraise will go toward supporting the company's products in their mid-stage trials for cancer and fibrosis. According to the release, Tvardi's lead product, TTI-101, is being studied in a Phase 1 trial of patients with advanced solid tumors who have failed all lines of therapy. So far, the drug has been well-received and shown multiple durable radiographic objective responses in the cancer patients treated.

Dr. Keith Flaherty, who is a member of Tvardi's scientific advisory board and professor of medicine at Harvard Medical School, offered his support of the company.

"STAT3 is a compelling and validated target. Beyond its clinical activity, Tvardi's lead molecule, TTI-101, has demonstrated direct downregulation of STAT3 in patients," he says in the release. "As a physician, I am eager to see the potential of Tvardi's molecules in diseases of high unmet medical need where STAT3 is a key driver."

Trending News